List of Excipients in Branded Drug CAPASTAT SULFATE

Capastat Sulfate Excipient Strategy and Commercial Opportunities

Last updated: September 21, 2026

Capastat Sulfate is the historical injectable formulation of capreomycin sulfate, an aminoglycoside-like cyclic peptide used in multidrug-resistant tuberculosis. Its commercial opportunity is limited by declining use of injectable tuberculosis agents, serious nephrotoxicity and ototoxicity, the availability of newer oral therapies, and the absence of a strong modern brand franchise. The most credible product-development opportunity is a low-excipient, preservative-free generic or institutional presentation focused on stability, reconstitution, supply reliability and global-access markets.

What is Capastat Sulfate and how is it administered?

Capastat Sulfate contains capreomycin sulfate for intramuscular or intravenous administration after reconstitution. The historical product was supplied as a sterile lyophilized powder in single-dose vials, generally containing capreomycin sulfate equivalent to 1 gram of capreomycin.[1]

Product attribute	Capastat Sulfate profile
Active ingredient	Capreomycin sulfate
Drug class	Antimycobacterial peptide antibiotic
Primary historical use	Multidrug-resistant tuberculosis
Dosage form	Sterile lyophilized powder
Administration	Intramuscular or intravenous after reconstitution
Typical strength	1 g vial
Preservatives	Historically absent from the single-dose formulation
Reconstitution	Sterile water or compatible parenteral diluent, according to labeling
Key safety risks	Nephrotoxicity, ototoxicity, neuromuscular blockade, electrolyte abnormalities
Commercial setting	Hospital, tuberculosis program and public-health procurement

Capreomycin was generally used when first-line therapy failed or when resistance limited alternatives. Historical treatment courses could extend for months, increasing the importance of renal monitoring, administration burden and cumulative toxicity.[1,2]

The U.S. FDA labeling reflects the historical role of capreomycin. Current tuberculosis guidance has reduced the role of injectable agents because oral regimens containing bedaquiline, pretomanid, linezolid and other agents can provide effective treatment with less injection-related burden.[2,3]

What excipients are used in Capastat Sulfate?

The historical Capastat formulation was designed around a minimal-excipient architecture. The vial contained the active drug as a sterile powder rather than a liquid formulation with buffers, preservatives, tonicity agents or solubilizers.[1]

This approach has several technical advantages:

• Lower risk of excipient-related incompatibility.
• Reduced risk of preservative toxicity in a medically fragile population.
• Fewer extractables and leachables concerns.
• A simpler regulatory bridge to the reference product.
• Lower manufacturing complexity.
• Better suitability for lyophilized storage and international distribution.

The formulation challenge is therefore less about adding excipients and more about controlling the active substance, residual moisture, cake structure, reconstitution time and vial-closure performance.

Likely excipient strategy for a modern generic

A generic developer should first evaluate whether the product can remain effectively excipient-free or use only the minimum quantity of a bulking or stabilizing agent. Potential excipient classes include:

Excipient class	Potential purpose	Commercial and regulatory assessment
Mannitol	Bulking agent and cake formation	Common in lyophilized injectables; may alter reconstitution and osmolality
Glycine	Bulking or stabilizing function	Requires compatibility and pH evaluation
Sucrose or trehalose	Stabilization during freezing and drying	May improve solid-state stability but increases formulation complexity
Phosphate buffer	pH control	May create precipitation or stability issues with sulfate-containing material
Citrate buffer	pH control	Requires compatibility testing and injection-site assessment
Sodium chloride	Tonicity adjustment after reconstitution	Usually unnecessary if the product is administered with a compatible diluent
Benzyl alcohol or parabens	Preservation in multidose systems	Poor fit for a single-dose tuberculosis injectable
EDTA	Chelation and stability control	Limited commercial rationale absent evidence of metal-catalyzed degradation

The preferred strategy is a single-dose, preservative-free vial with no unnecessary buffer. A formulation containing mannitol could improve the physical appearance of the lyophilized cake, but it would create a new composition that requires comparative stability, reconstitution and safety work. A formulation that closely matches the reference product may have a simpler regulatory path if the reference composition and manufacturing process are sufficiently documented.

What formulation patents protect Capastat Sulfate?

Capastat Sulfate is an older product, and the principal commercial protection historically would have come from compound, formulation and regulatory exclusivity that has long expired. No meaningful modern patent moat should be assumed for the basic capreomycin sulfate injectable presentation.

Protection category	Likely status for Capastat Sulfate
Original compound patent	Expired
Original injectable formulation protection	Expired or commercially immaterial
Product-specific FDA exclusivity	Expired
Basic lyophilized-vial formulation	Vulnerable to generic development
Manufacturing know-how	May remain confidential and commercially relevant
Modern delivery-system patents	No established Capastat-specific moat
Method-of-use patents	Limited practical value given the age of the indication
Orange Book protection	No material current exclusivity expected

The absence of a patent barrier does not eliminate development risk. A competitor may still face challenges relating to sterile manufacturing, active pharmaceutical ingredient supply, analytical methods, stability data and regulatory requirements for injectable products.

What is the FDA regulatory status of Capastat Sulfate?

The regulatory status must be separated from the historical labeling. Capreomycin has an established FDA history as an injectable antimycobacterial drug, but the product’s commercial availability and marketing status should not be equated with current clinical preference.

The FDA-approved label historically identified capreomycin for use in combination with other antituberculosis drugs when primary agents were ineffective or unsuitable.[1] The drug was not intended as monotherapy because resistance can develop rapidly.

For a new U.S. applicant, the likely commercial route would be an abbreviated new drug application if an appropriate reference product remains available and FDA requirements can be met. If no suitable reference product is available or the product is no longer actively marketed in a manner usable for ANDA purposes, a different regulatory pathway could be required.

Key regulatory workstreams include:

1. Demonstrating pharmaceutical equivalence.
2. Establishing sterility and container-closure integrity.
3. Matching strength and route of administration.
4. Validating assay, related substances and potency methods.
5. Demonstrating acceptable reconstitution time.
6. Characterizing degradation products.
7. Establishing stability under ICH conditions.
8. Evaluating compatibility with infusion diluents and administration materials.
9. Addressing renal and auditory safety warnings in labeling.
10. Confirming current FDA requirements for the proposed reference product and dosage form.

How important are excipients in generic approval?

For a sterile lyophilized injectable, excipients can affect more than inactive-ingredient listing. They can change the product’s physical and clinical performance.

Regulators are likely to focus on:

• Reconstitution time.
• Clarity of the reconstituted solution.
• Visible and subvisible particles.
• pH and osmolality.
• Delivered dose.
• Stability after reconstitution.
• Compatibility with infusion bags and tubing.
• Container-closure integrity.
• Sterility assurance.
• Endotoxin levels.
• Residual moisture.
• Impurity and degradation profiles.

A formulation that adds a stabilizer may offer better shelf life but increase the burden of comparative evaluation. A formulation with fewer excipients may simplify the product profile but place greater reliance on lyophilization-cycle control and active-substance quality.

The best development target is a formulation that preserves the reference product’s low-excipient profile while improving manufacturing robustness and global storage performance.

What commercial opportunities exist for Capastat Sulfate?

The opportunity is concentrated in specialized and public-sector markets rather than broad retail distribution.

Public-health and tuberculosis procurement

Capreomycin may retain limited use where resistance patterns, treatment history or lack of access to newer oral drugs leave few alternatives. Potential customers include:

• National tuberculosis programs.
• Government hospitals.
• Military and correctional-health systems.
• Humanitarian procurement agencies.
• Specialized infectious-disease hospitals.
• Markets with constrained access to bedaquiline-based regimens.

Global demand is structurally weaker than it was when injectable agents formed a larger part of multidrug-resistant tuberculosis treatment. The World Health Organization has shifted treatment guidance toward all-oral regimens when clinically appropriate.[3]

Supply-reliability opportunity

The strongest commercial positioning is likely to be dependable supply rather than clinical differentiation. A manufacturer could compete through:

• Dual-source active pharmaceutical ingredient procurement.
• Long-dated expiry.
• Controlled cold-chain or room-temperature storage, if supported by data.
• Small-volume hospital packs.
• Government tender pricing.
• Reliable batch release.
• Regional packaging and distribution.
• Clear reconstitution instructions.

Contract manufacturing and licensing

Capreomycin sulfate could support a focused contract-manufacturing model for companies that lack sterile lyophilization capacity. Potential structures include:

Model	Opportunity
Finished-dose licensing	License a ready-to-file or approved vial
Contract lyophilization	Manufacture under a partner’s marketing authorization
Regional commercialization	Grant rights in tuberculosis-endemic markets
Government supply agreement	Secure volume through public procurement
API-to-finished-product integration	Control supply and reduce vendor risk

The limited market size makes a licensing deal more attractive when the partner already has sterile injectable infrastructure, an established tuberculosis portfolio or public-sector tender access.

What manufacturing and intellectual-property barriers exist?

The key barrier is technical execution rather than patent exclusion.

Sterile lyophilization

Capreomycin sulfate must be processed through a validated sterile manufacturing system. The development program must control:

• Bioburden before sterilizing filtration.
• Filtration compatibility.
• Aseptic filling.
• Lyophilization cycle reproducibility.
• Cake collapse and shrinkage.
• Residual moisture.
• Particulate matter.
• Stopper and seal performance.

A low-volume niche product may have unfavorable economics if the manufacturer lacks existing capacity for sterile powders.

Active pharmaceutical ingredient supply

API sourcing can be a larger risk than excipient selection. A qualified supplier must support:

• Consistent sulfate content and potency.
• Low impurity levels.
• Reliable microbiological control.
• Adequate batch scale.
• Regulatory documentation.
• Long-term supply continuity.

A single-source API arrangement could undermine the commercial value of the finished product, especially in public tenders where supply interruptions create significant reputational and contractual exposure.

Trade-secret protection

Although basic formulation patents are unlikely to provide exclusivity, process knowledge may remain valuable. This includes:

• API conditioning before filling.
• pH and moisture control.
• Freezing rate.
• Primary and secondary drying parameters.
• Reconstitution performance.
• Container-closure selection.
• Stability-indicating analytical methods.

These process elements can create a practical barrier even when the product is legally open to competition.

Which companies are challenging Capastat Sulfate?

No broad, high-value patent challenge market is expected for Capastat Sulfate. The product is better viewed as an off-patent sterile injectable opportunity than as a contested branded product.

Potential competitors would include:

• Generic sterile-injectable manufacturers.
• Companies with existing tuberculosis portfolios.
• Regional manufacturers in high-burden countries.
• Public-sector suppliers.
• Contract development and manufacturing organizations with lyophilization capacity.

Competition is likely to center on price, registration status, tender eligibility, supply continuity and manufacturing compliance. Paragraph IV litigation is unlikely to be a central commercial issue because the relevant product and formulation protections are old.

How does Capastat Sulfate compare with newer tuberculosis drugs?

Attribute	Capastat Sulfate	Bedaquiline-based oral therapy	Pretomanid-containing regimen
Route	Injection	Oral	Oral
Main historical role	Resistant tuberculosis salvage therapy	Core component in modern resistant-TB regimens	Used in defined combination regimens
Administration burden	High	Lower	Lower
Renal and auditory risk	Material	Different safety profile	Different safety profile
Patent exposure	Generally low	Higher, depending on product and jurisdiction	Higher, depending on product and jurisdiction
Commercial growth profile	Declining or niche	Established modern MDR-TB demand	Specialized regimen demand
Excipient opportunity	Lyophilized sterile powder	Tablets or fixed-dose combinations	Tablets or combination products

The competitive disadvantage is clinical convenience. Capreomycin’s remaining value is strongest where oral alternatives are unavailable, contraindicated, inaccessible or unsuitable based on susceptibility and treatment history.

What generic launch scenarios exist?

Scenario 1: Public-sector niche launch

A manufacturer launches a preservative-free 1 g vial for national tuberculosis programs. The product competes on tender price and supply assurance. This is the most realistic scenario.

Scenario 2: Regional registration strategy

A company registers the product in selected high-burden markets rather than pursuing broad global approval. The strategy reduces regulatory cost but limits scale.

Scenario 3: Portfolio bundling

Capreomycin is added to a broader tuberculosis portfolio containing oral agents, diagnostics or other injectables. Bundling improves procurement relevance and reduces standalone commercial risk.

Scenario 4: Contract supply without a new brand

A manufacturer supplies the product to an established tuberculosis company or government contractor. This avoids the cost of building a separate commercial organization.

Scenario 5: Reformulated product

A developer pursues a more stable or easier-to-reconstitute lyophilized formulation. The technical differentiation could support a limited product advantage, but clinical demand would still be constrained by treatment guidelines.

What is the revenue exposure and market outlook?

Revenue exposure is likely to be low relative to modern tuberculosis products. The addressable market is limited by:

• Reduced guideline preference for injectable agents.
• Long treatment duration but falling use.
• Low pricing in public procurement.
• Specialist distribution requirements.
• Safety monitoring costs.
• Potential substitution by oral regimens.
• Small patient populations in higher-income countries.

A commercial model can still work when manufacturing assets already exist and the product is sold as part of a larger infectious-disease portfolio. A greenfield facility built solely for Capastat Sulfate would face substantial utilization risk.

Key Takeaways

• Capastat Sulfate is a historical capreomycin sulfate injectable for multidrug-resistant tuberculosis.
• The preferred excipient strategy is a sterile, single-dose, preservative-free lyophilized powder with minimal formulation complexity.
• Mannitol, glycine, sucrose and trehalose are technically possible excipients, but each creates additional compatibility and stability work.
• Basic formulation and method-of-use patent protection should be treated as expired or commercially weak.
• The main barriers are sterile manufacturing, API quality, stability, regulatory execution and supply continuity.
• FDA approval history does not mean that capreomycin is a preferred modern therapy. WHO guidance favors all-oral regimens when appropriate.
• The strongest commercial opportunity is a low-cost public-sector or regional generic supplied by a company with existing lyophilization capacity.
• Capastat Sulfate is not an attractive standalone high-growth pharmaceutical asset. It is more credible as a niche portfolio product, contract-manufacturing program or public-health supply opportunity.

FAQs

Is Capastat Sulfate still commercially attractive?

Only on a limited basis. Its opportunity is concentrated in resistant-tuberculosis markets where injectable therapy remains necessary or oral alternatives are unavailable.

Which excipient is best for a generic capreomycin injection?

The best initial strategy is to minimize excipients and preserve a preservative-free lyophilized presentation. Mannitol may be evaluated as a bulking agent, but it should not be added without evidence of improved manufacturability or stability.

Does Capastat Sulfate have meaningful patent protection?

The original drug and basic injectable presentation are old. Commercial protection is more likely to arise from manufacturing know-how, regulatory approvals, API supply and tender access than from active composition patents.

Could capreomycin be developed as a ready-to-use liquid injection?

A liquid presentation would increase stability, preservative, container-closure and shipping requirements. A lyophilized vial remains the lower-risk platform unless substantial liquid stability can be demonstrated.

Is there a biosimilar pathway for Capastat Sulfate?

No. Capreomycin sulfate is a small-molecule antimicrobial peptide rather than a biologic managed through the conventional biosimilar pathway. A generic-drug or other applicable abbreviated pathway is more relevant.

References

1. U.S. Food and Drug Administration. (n.d.). Capastat sulfate: Prescribing information.
2. Centers for Disease Control and Prevention. (2003). Treatment of tuberculosis: American Thoracic Society, CDC, and Infectious Diseases Society of America. MMWR Recommendations and Reports, 52(RR-11), 1-77.
3. World Health Organization. (2022). WHO consolidated guidelines on tuberculosis: Module 4: Treatment: Drug-resistant tuberculosis treatment. World Health Organization.